JP2022523971A5 - - Google Patents

Info

Publication number
JP2022523971A5
JP2022523971A5 JP2021552602A JP2021552602A JP2022523971A5 JP 2022523971 A5 JP2022523971 A5 JP 2022523971A5 JP 2021552602 A JP2021552602 A JP 2021552602A JP 2021552602 A JP2021552602 A JP 2021552602A JP 2022523971 A5 JP2022523971 A5 JP 2022523971A5
Authority
JP
Japan
Prior art keywords
amino acid
tcr
acid sequence
constant region
hla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021552602A
Other languages
English (en)
Japanese (ja)
Other versions
JP7727546B2 (ja
JP2022523971A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2020/051810 external-priority patent/WO2020178741A1/en
Publication of JP2022523971A publication Critical patent/JP2022523971A/ja
Publication of JP2022523971A5 publication Critical patent/JP2022523971A5/ja
Application granted granted Critical
Publication of JP7727546B2 publication Critical patent/JP7727546B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021552602A 2019-03-04 2020-03-03 T細胞受容体及びその使用方法 Active JP7727546B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813645P 2019-03-04 2019-03-04
US62/813,645 2019-03-04
PCT/IB2020/051810 WO2020178741A1 (en) 2019-03-04 2020-03-03 T cell receptors and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2022523971A JP2022523971A (ja) 2022-04-27
JP2022523971A5 true JP2022523971A5 (enExample) 2023-03-13
JP7727546B2 JP7727546B2 (ja) 2025-08-21

Family

ID=72336931

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021552602A Active JP7727546B2 (ja) 2019-03-04 2020-03-03 T細胞受容体及びその使用方法

Country Status (13)

Country Link
US (1) US12522644B2 (enExample)
EP (1) EP3935176A4 (enExample)
JP (1) JP7727546B2 (enExample)
KR (1) KR20210149048A (enExample)
CN (1) CN113795584B (enExample)
AU (1) AU2020231194A1 (enExample)
BR (1) BR112021017505A2 (enExample)
CA (1) CA3132431A1 (enExample)
IL (1) IL286046A (enExample)
MX (1) MX2021010541A (enExample)
SG (1) SG11202109591QA (enExample)
TW (1) TW202043250A (enExample)
WO (1) WO2020178741A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
CN113795584B (zh) 2019-03-04 2025-09-30 大学健康网络 T细胞受体及其使用方法
KR20210144737A (ko) 2019-03-04 2021-11-30 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
MX2021011462A (es) 2019-03-25 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.
WO2025096983A1 (en) * 2023-11-02 2025-05-08 Board Of Regents, The University Of Texas System Peptides and engineered t cell receptors targeting tpx2 antigen and methods of use

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2323632A1 (en) 1998-03-13 1999-09-16 Epimmune Inc. Hla-binding peptides and their uses
CA2388337C (en) * 1999-10-22 2013-01-08 Aventis Pasteur Limited Method of inducing and/or enhancing an immune response to tumor antigens
US6506875B1 (en) 2000-09-26 2003-01-14 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-C molecules and uses thereof
US8158357B2 (en) 2005-03-16 2012-04-17 Dna Genotek Inc. Compositions and method for storage of nucleic acid from bodily fluids
WO2008089053A2 (en) * 2007-01-12 2008-07-24 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Gp100-specific t cell receptors and related materials and methods of use
JP5292550B2 (ja) * 2007-03-23 2013-09-18 静岡県 T細胞レセプターβ鎖遺伝子及びα鎖遺伝子
EP2144935A2 (en) 2007-03-29 2010-01-20 Technion Research & Development Foundation Ltd. Antibodies, methods and kits for diagnosing and treating melanoma
KR101363928B1 (ko) 2007-06-11 2014-02-19 고쿠리츠다이가쿠호진 미에다이가쿠 특이적 유전자 발현 방법
EP2337795A2 (en) 2008-10-01 2011-06-29 Dako Denmark A/S Mhc multimers in cancer vaccines and immune monitoring
JP5756792B2 (ja) 2009-04-02 2015-07-29 ヴァクソン バイオテックVaxon Biotech 免疫療法のための潜在性hla−a24エピトープの同定、最適化及び使用
WO2011140284A2 (en) 2010-05-04 2011-11-10 Fred Hutchinson Cancer Research Center Conditional superagonist ctl ligands for the promotion of tumor-specific ctl responses
HRP20171164T1 (hr) 2010-09-20 2017-10-20 Biontech Cell & Gene Therapies Gmbh Antigen-specifični t stanični receptori i t stanični epitopi
PH12013501201A1 (en) 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
KR101503341B1 (ko) 2014-03-12 2015-03-18 국립암센터 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법
WO2015188839A2 (en) * 2014-06-13 2015-12-17 Immudex Aps General detection and isolation of specific cells by binding of labeled molecules
US20170333480A1 (en) 2014-11-05 2017-11-23 Board Of Regents, The University Of Texas System Gene modified immune effector cells and engineered cells for expansion of immune effector cells
NL2014935B1 (en) 2015-06-08 2017-02-03 Applied Immune Tech Ltd T cell receptor like antibodies having fine specificity.
DK3399985T3 (da) 2016-01-06 2022-03-21 Health Research Inc Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer
WO2017185169A1 (en) 2016-04-27 2017-11-02 University Health Network (Uhn) Pept1de-hla complexes and methods of producing same
WO2020178739A1 (en) 2019-03-04 2020-09-10 University Health Network T cell receptors and methods of use thereof
KR20210144740A (ko) 2019-03-04 2021-11-30 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
KR20210144737A (ko) 2019-03-04 2021-11-30 유니버시티 헬스 네트워크 T 세포 수용체 및 이의 사용 방법
US20220168346A1 (en) 2019-03-04 2022-06-02 University Health Network T cell receptors and methods of use thereof
CN113795584B (zh) 2019-03-04 2025-09-30 大学健康网络 T细胞受体及其使用方法
EP3935175A4 (en) 2019-03-04 2023-01-04 University Health Network T-LYMPHOCYTE RECEPTORS AND METHODS OF USE THEREOF
JP7748874B2 (ja) 2019-03-04 2025-10-03 ユニバーシティー ヘルス ネットワーク T細胞受容体及びその使用方法
MX2021011462A (es) 2019-03-25 2021-12-15 Univ Health Network Receptores de linfocitos t y metodos de uso de los mismos.

Similar Documents

Publication Publication Date Title
JP2022527267A5 (enExample)
JP2022523554A5 (enExample)
JP2022524994A5 (enExample)
JP2022524993A5 (enExample)
JP2022523552A5 (enExample)
JP2022523971A5 (enExample)
JP2022523553A5 (enExample)
Baxevanis et al. Cancer immunotherapy
Batlevi et al. Novel immunotherapies in lymphoid malignancies
Kershaw et al. Gene-engineered T cells for cancer therapy
JP2022524992A5 (enExample)
US20200038443A1 (en) Multi-function and multi-targeting car system and methods for use thereof
Merhavi-Shoham et al. Adoptive cell therapy for metastatic melanoma
CN109694854B (zh) 通用型嵌合抗原受体t细胞制备技术
JP2020509767A5 (enExample)
Tsang et al. Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
Shilyansky et al. T-cell receptor usage by melanoma-specific clonal and highly oligoclonal tumor-infiltrating lymphocyte lines.
Junghans The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective
Murad et al. Advances in the use of natural receptor-or ligand-based chimeric antigen receptors (CARs) in haematologic malignancies
US20170232070A1 (en) Combination Methods for Immunotherapy
JP2023512452A (ja) Bcma指向性細胞免疫療法組成物および方法
JP2022543059A5 (enExample)
US11951131B2 (en) Anti-SLAMF7 chimeric antigen receptors
KR20240032732A (ko) 암 면역요법을 위한 투약 요법
JP2020533962A5 (enExample)